
Novo Nordisk and OpenAI Partner to Redefine the Future of Drug Discovery
In a move that signals the accelerating convergence of artificial intelligence and global healthcare, Novo Nordisk has announced a strategic partnership with OpenAI aimed at transforming how medicines are discovered, developed, and delivered. The collaboration represents more than a technology upgrade. It is a strategic pivot toward a new model








